Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Conrad A Vink

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Molecular Therapy. Methods & Clinical Development|June 7, 2021
The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titreNathan P Sweeney, Conrad A Vink
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2010
Hybrid lentiviral vectorsWaseem Qasim, Conrad A Vink, Adrian J Thrasher
Molecular Therapy. Methods & Clinical Development|November 4, 2020
Development of a Novel Competitive qRT-PCR Assay to Measure Relative Lentiviral Packaging EfficiencyEirini Vamva, Andrew M L Lever, Conrad A Vink, et al.
Nucleic Acids Research|December 20, 2021
A novel role for gag as a cis-acting element regulating RNA structure, dimerization and packaging in HIV-1 lentiviral vectorsEirini Vamva, Alex Griffiths, Conrad A Vink, et al.
Scientific Reports|June 9, 2021
HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiencyHelin Sertkaya, Mattia Ficarelli, Nathan P Sweeney, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2009
Sleeping beauty transposition from nonintegrating lentivirusConrad A Vink, H Bobby Gaspar, Richard Gabriel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 5, 2006
The integration profile of EIAV-based vectorsCaroline V Hacker, Conrad A Vink, Theresa W Wardell, et al.
Scientific Reports|August 30, 2017
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 3, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 18, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Molecular Therapy. Methods & Clinical Development|June 7, 2021
The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titreNathan P Sweeney, Conrad A Vink
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2010
Hybrid lentiviral vectorsWaseem Qasim, Conrad A Vink, Adrian J Thrasher
Molecular Therapy. Methods & Clinical Development|November 4, 2020
Development of a Novel Competitive qRT-PCR Assay to Measure Relative Lentiviral Packaging EfficiencyEirini Vamva, Andrew M L Lever, Conrad A Vink, et al.
Nucleic Acids Research|December 20, 2021
A novel role for gag as a cis-acting element regulating RNA structure, dimerization and packaging in HIV-1 lentiviral vectorsEirini Vamva, Alex Griffiths, Conrad A Vink, et al.
Scientific Reports|June 9, 2021
HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiencyHelin Sertkaya, Mattia Ficarelli, Nathan P Sweeney, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2009
Sleeping beauty transposition from nonintegrating lentivirusConrad A Vink, H Bobby Gaspar, Richard Gabriel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 5, 2006
The integration profile of EIAV-based vectorsCaroline V Hacker, Conrad A Vink, Theresa W Wardell, et al.
Scientific Reports|August 30, 2017
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 3, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 18, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Pageof 2